Literature DB >> 21872611

Absence of equilibrative nucleoside transporter 1 in ENT1 knockout mice leads to altered nucleoside levels following hypoxic challenge.

Jennifer B Rose1, Zlatina Naydenova, Andrew Bang, Azza Ramadan, Jost Klawitter, Kristin Schram, Gary Sweeney, Almut Grenz, Holger Eltzschig, James Hammond, Doo-Sup Choi, Imogen R Coe.   

Abstract

AIMS: Equilibrative nucleoside transporters (ENT) modulate the flux of adenosine. The ENT1-null (KO) mouse heart is endogenously cardioprotected but the cellular basis of this phenotype is unknown. Therefore, we investigated the cellular mechanisms underlying ENT1-mediated cardioprotection. MAIN
METHODS: Circulating adenosine levels were measured in WT and KO mice. Cellular levels of nucleosides and nucleotides were investigated in isolated adult cardiomyocytes from WT and KO mice using HPLC following hypoxic challenge (30 min, 2% O(2)). Changes in hypoxic gene expression were analyzed by PCR arrays and cAMP levels were measured to investigate contributions from adenosine receptors. KEY
FINDINGS: Circulating adenosine levels were significantly higher in KO (416±42nmol/l, n=12) compared to WT animals (208±21, n=13, p<0.001). Absence of ENT1 led to an elevated expression of genes involved in cardioprotective pathways compared to WT cardiomyocytes. Following hypoxic challenge, extracellular adenosine levels were significantly elevated in KO (4360±1840 pmol/mg protein) versus WT cardiomyocytes (3035±730 pmol/mg protein, n≥12, p<0.05). This effect was enhanced in the presence of dipyridamole (30 μM), which inhibits ENT1 and ENT2. Enhanced extracellular adenosine levels in ENT1-null cardiomyocytes appeared to come from a pool of extracellular nucleotides including IMP, AMP and ADP. Adenosine receptor (AR) activation mimicked increases in cAMP levels due to hypoxic challenge suggesting that ENT1 modulates AR-dependent signaling. SIGNIFICANCE: ENT1 contributes to modulation of extracellular adenosine levels and subsequent purinergic signaling via ARs. ENT1-null mice possess elevated circulating adenosine levels and reduced cellular uptake resulting in a perpetually cardioprotected phenotype.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21872611     DOI: 10.1016/j.lfs.2011.08.007

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  16 in total

Review 1.  Equilibrative nucleoside transporters-A review.

Authors:  Rebba C Boswell-Casteel; Franklin A Hays
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2016-10-19       Impact factor: 1.381

2.  Tubuloglomerular feedback and renal function in mice with targeted deletion of the type 1 equilibrative nucleoside transporter.

Authors:  Lingli Li; Diane Mizel; Yuning Huang; Christoph Eisner; Marion Hoerl; Manfred Thiel; Jurgen Schnermann
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-26

Review 3.  Regulation of bone and cartilage by adenosine signaling.

Authors:  Lauren C Strazzulla; Bruce N Cronstein
Journal:  Purinergic Signal       Date:  2016-07-29       Impact factor: 3.765

4.  Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Authors:  Megan Li; Flora Mulkey; Chen Jiang; Bert H O'Neil; Bryan P Schneider; Fei Shen; Paula N Friedman; Yukihide Momozawa; Michiaki Kubo; Donna Niedzwiecki; Howard S Hochster; Heinz-Josef Lenz; James N Atkins; Hope S Rugo; Susan Halabi; William Kevin Kelly; Howard L McLeod; Federico Innocenti; Mark J Ratain; Alan P Venook; Kouros Owzar; Deanna L Kroetz
Journal:  Clin Cancer Res       Date:  2018-06-05       Impact factor: 12.531

Review 5.  Regulation of adenosine levels during cerebral ischemia.

Authors:  Stephanie Chu; Wei Xiong; Dali Zhang; Hanifi Soylu; Chao Sun; Benedict C Albensi; Fiona E Parkinson
Journal:  Acta Pharmacol Sin       Date:  2012-10-15       Impact factor: 6.150

6.  The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity.

Authors:  Azza Ramadan; Zlatina Naydenova; Katarina Stevanovic; Jennifer B Rose; Imogen R Coe
Journal:  Purinergic Signal       Date:  2013-10-27       Impact factor: 3.765

7.  Type 1 equilibrative nucleoside transporter regulates astrocyte-specific glial fibrillary acidic protein expression in the striatum.

Authors:  David J Hinton; Moonnoh R Lee; Jin Sung Jang; Doo-Sup Choi
Journal:  Brain Behav       Date:  2014-09-19       Impact factor: 2.708

8.  Changes in aortic reactivity associated with the loss of equilibrative nucleoside transporter 1 (ENT1) in mice.

Authors:  K Arielle Best; Derek B Bone; Gonzalo Vilas; Robert Gros; James R Hammond
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

9.  The equilibrative nucleoside transporter ENT1 is critical for nucleotide homeostasis and optimal erythropoiesis.

Authors:  Mahmoud Mikdar; Pedro González-Menéndez; Xiaoli Cai; Yujin Zhang; Marion Serra; Abdoul K Dembele; Anne-Claire Boschat; Sylvia Sanquer; Cerina Chhuon; Ida Chiara Guerrera; Marc Sitbon; Olivier Hermine; Yves Colin; Caroline Le Van Kim; Sandrina Kinet; Narla Mohandas; Yang Xia; Thierry Peyrard; Naomi Taylor; Slim Azouzi
Journal:  Blood       Date:  2021-06-24       Impact factor: 25.476

10.  Aberrant bone density in aging mice lacking the adenosine transporter ENT1.

Authors:  David J Hinton; Meghan E McGee-Lawrence; Moonnoh R Lee; Hoi K Kwong; Jennifer J Westendorf; Doo-Sup Choi
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.